Rockwell MedicalRMTI -5.73%30 Days Payable is 17.21 as of Mar. 2026, which is 22% below its 10-year median of 22.20. GuruFocus rates RMTI with a GF Score™ of 30/100 and a GF Value™ of $0.87 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 921 Drug Manufacturers companies, Rockwell Medical ranks worse than 97.39% on this metric.
The historical rank and industry rank for Rockwell Medical's Days Payable or its related term are showing as below:
RMTI'
s Days Payable Range Over the Past 10 Years
Min: 13.52 Med: 22.2 Max: 38.64
Current: 13.52
During the past 13 years, Rockwell Medical's highest Days Payable was 38.64. The lowest was 13.52. And the median was 22.20.
RMTI's Days Payable is ranked worse than 97.39% of 921
companies
in the Drug Manufacturers industry
Industry Median: 90.69
vs RMTI: 13.52
Rockwell Medical's Days Payable
increased
from Mar. 2025 (13.78) to Mar. 2026 (17.21).
It may suggest that Rockwell Medicaldelayed paying its suppliers.
Rockwell Medical Days Payable Related Terms
Rockwell Medical Days Payable Historical Data
* Premium members only.
The historical data trend for Rockwell Medical's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Rockwell Medical's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rockwell Medical Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Rockwell Medical's Days Payable distribution charts can be found below:
* The bar in red indicates where Rockwell Medical's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Rockwell Medical's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rockwell Medical (RMTI) has a Days Payable of 17.21 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Rockwell Medical and its competitors. This is 22% below median its historical median of 22.20. Over the past decade, Rockwell Medical's Days Payable has ranged from 13.52 to 38.64. According to the industry distribution chart, Rockwell Medical ranks #897 out of 921 companies in the Drug Manufacturers industry, placing it in the top 97.4%.
Is Rockwell Medical's Days Payable too high?
Rockwell Medical's current Days Payable of 17.21 is 22% below median its 10-year median of 22.20. Over the past 10 years, this metric has ranged from a low of 13.52 to a high of 38.64. The Drug Manufacturers industry median Days Payable is 90.69. Rockwell Medical's value of 17.21 is 81% below this industry median. Based on the distribution chart, Rockwell Medical ranks #897 out of 921 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Rockwell Medical has a GF Score™ of 30/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Rockwell Medical's Days Payable compare to CPHI and TXMD?
According to the Drug Manufacturers industry distribution chart, Rockwell Medical ranks #897 out of 921 companies for Days Payable. This places Rockwell Medical in the lower half of its industry. The industry median Days Payable is 90.69. Rockwell Medical's value of 17.21 is 81% below this benchmark. Historically, Rockwell Medical's own Days Payable has ranged from 13.52 to 38.64 over the past decade. While the company's 10-year median is 22.20 vs. the industry median of 90.69, Rockwell Medical has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.69, based on 921 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rockwell Medical's current Days Payable of 17.21 is 81% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Rockwell Medical and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rockwell Medical's current Days Payable is 17.21, which is 22% below median its own 10-year median of 22.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rockwell Medical stock overvalued right now?
Based on GuruFocus' analysis, Rockwell Medical (RMTI) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.87, compared to a current price of $5.19 — trading 496.6% above its estimated fair value. The current Days Payable is 17.21, which is 22% below median its 10-year median of 22.20 and 81% below the Drug Manufacturers industry median of 90.69. Rockwell Medical's overall GF Score™ is 30/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Rockwell Medical (RMTI), the current Days Payable is 17.21 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Rockwell Medical (RMTI) Overvalued in 2026?
Based on GuruFocus' analysis, Rockwell Medical stock appears to be overvalued.
The current stock price of $5.19 is trading 496.6% above its estimated GF Value™ of $0.87.
GuruFocus considers Rockwell Medical to be Significantly Overvalued.
Key valuation signals for RMTI:
Days Payable: 17.21 (22% below median its 10-year median of 22.20)
GF Value™: $0.87 vs. price of $5.19 (496.6% above fair value)
Industry Position: 81% below the Drug Manufacturers median (#897 of 921)
No single metric tells the full story. See the RMTI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Rockwell Medical Inc is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers. It is a supplier of liquid bicarbonate concentrates, acid, and dry bicarbonate concentrates for dialysis patients in the United States. The company's products include CitraPure citric acid concentrate, RenalPure liquid acid concentrate, and SteriLyte bicarbonate concentrate, among others. The company delivers the majority of its hemodialysis concentrates products and mixers to dialysis clinics throughout the United States and internationally, utilizing its own delivery trucks and third-party carriers.
30GF Score
Get the complete analysis for RMTI
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RMTI has been successfully added to your 
